Imbrium will leverage TetraGenetics' proprietary TetraExpress system to advance monoclonal antibodies that target specific ion channels that are scientifically important in the modulation of pain sensation.
The goal of this collaborative effort is to bring to market long-acting, non-opioid therapeutics that can treat a variety of pain conditions.
Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.
We are pursuing treatments for disorders of the central nervous system, oncology chemotherapeutics, and non-opioid approaches to the management of pain.
As an operating subsidiary of Purdue Pharma L.P., Imbrium strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide.
We have built a robust and diversified pipeline of investigational drug candidates, and we actively collaborate with industry and academic partners to identify and advance future impactful medicines.
TetraGenetics is a pre-clinical drug discovery and development company.
It uses proprietary technology (TetraExpress) to discover large molecule drugs targeting ion channel and other membrane proteins associated with many human diseases.
The company's focus is the discovery and development of first-in-class biologics for autoimmune diseases and pain.
TetraGenetics establishes collaborative partnerships with major biotech companies for antibody drug discovery and pursues novel approaches to advance its proprietary drug pipeline.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials